ISPOR 2025
Landmark will be at ISPOR 2025. Join us to learn about our capabilities!
Landmark and IQVIA collaboration
White paper on best practices for RWE for regulatory filings
Attrition rates and RW outcomes for mBC patients
Landmark, IQVIA, and AstraZeneca collaboration
RWE Capabilities
RWE Capabilities
End to End Study Execution
End to End Study Execution

Services

Regulatory-Grade Solutions


We design and generate RWE for regulatory submissions including externally controlled trials (ECTs), natural history, benchmarking studies, and epidemiological support on orphan drug applications, pediatric study plans, diversity plans, and (s)BLAs/(s)NDAs.

Observational Studies

We design and conduct a range of observational studies including burden of disease, comparative effectiveness & safety, and external control arms. We provide end-to-end execution including study design, protocol and analysis plan writing, analysis, study report, and publications.

Literature Reviews

We conduct targeted or systematic literature reviews to inform comparative effectiveness and confounder selection, incidence and prevalence across indications, treatment patterns, and outcomes.

Data Landscaping

We identify suitable data sources for novel research questions and conduct data assessments by indication to determine fitness of data. We have extensive experience with medical claims databases, electronic health record data, genomic, and registry data.

Health Outcomes Research

Design and conduct of cost effectiveness studies and data to support HTA/payor needs.

Medical Writing

Our writing services include protocol and statistical analysis plan writing, and abstract, poster and manuscript development. Experience with medical writing in the context of real-world evidence.

SUCCESS STORIES


Screenshot 2024-11-01 201701
Screenshot 2024-11-01 211945

Looking for support in generating RWE?

 
 
 
 
 

We offer flexible and custom solutions to meet your needs. Contact us to initiate a dialogue.

unsplash